Do you see this as a drug that, if successful, could turn DYAX's HAE fortunes around?
Well, with self-administered subQ, less frequent dosing, better efficacy than C1 inhibitors and without black-box it would be a winner in the prophylaxis indication, but as you've noted - it is not even in the clinic yet.
Market Data 
Markets 
AI
